It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Apoptosis and senescence are two mutually exclusive cell fate programs that can be activated by stress. The factors that instruct cells to enter into senescence or apoptosis are not fully understood, but both programs can be regulated by the stress kinase p38α. Using an inducible system that specifically activates this pathway, we show that sustained p38α activation suffices to trigger massive autophagosome formation and to enhance the basal autophagic flux. This requires the concurrent effect of increased mitochondrial reactive oxygen species production and the phosphorylation of the ULK1 kinase on Ser-555 by p38α. Moreover, we demonstrate that macroautophagy induction by p38α signaling determines that cancer cells preferentially enter senescence instead of undergoing apoptosis. In agreement with these results, we present evidence that the induction of autophagy by p38α protects cancer cells from chemotherapy-induced apoptosis by promoting senescence. Our results identify a new mechanism of p38α-regulated basal autophagy that controls the fate of cancer cells in response to stress.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The Barcelona Institute of Science and Technology, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain (GRID:grid.473715.3)
2 The Barcelona Institute of Science and Technology, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain (GRID:grid.473715.3); University of Barcelona, Faculty of Biology, Department of Biochemistry and Molecular Biomedicine, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
3 The Barcelona Institute of Science and Technology, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain (GRID:grid.473715.3); ICREA, Pg. Lluís Companys 23, Barcelona, Spain (GRID:grid.425902.8) (ISNI:0000 0000 9601 989X)